• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Non-Vitamin K Oral Anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: Time for a reappraisal
Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) have changed the landscape for stroke prevention in atrial fibrillation (AF). Given the huge burden of AF in Asians, more attention to stroke prevention is clearly needed. Aiming to provide an overview and reappraisal of stroke prevention in Asians with AF, we searched MEDLINE for information on NOACs in Asians. In addition, abstracts from national and international cardiovascular meetings were studied to identify unpublished studies.In the 4 recent Phase 3 trials comparing NOACs to warfarin, a consistent pattern is evident.
Source: International Journal of Cardiology - November 26, 2014 Category: Cardiology Authors: Gregory Y.H. Lip, Kang-Ling Wang, Chern-En Chiang Tags: Review Source Type: research

Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: Time for a reappraisal
Non-vitamin K antagonist oral anticoagulants (NOACs) have changed the landscape for stroke prevention in atrial fibrillation (AF). Given the huge burden of AF in Asians, more attention to stroke prevention is clearly needed. Aiming to provide an overview and reappraisal of stroke prevention in Asians with AF, we searched MEDLINE for information on NOACs in Asians. In addition, abstracts from national and international cardiovascular meetings were studied to identify unpublished studies.In the 4 recent Phase 3 trials comparing NOACs to warfarin, a consistent pattern is evident.
Source: International Journal of Cardiology - November 26, 2014 Category: Cardiology Authors: Gregory Y.H. Lip, Kang-Ling Wang, Chern-En Chiang Tags: Review Source Type: research

Effect of prior anticoagulation therapy on stroke severity and in-hospital outcomes in patients with acute ischemic stroke and atrial fibrillation
We aimed to assess the prevalence of prior anticoagulation therapy (warfarin or non-vitamin K antagonist oral anticoagulants [NOACs]) among patients with acute ischemic stroke (AIS) and atrial fibrillation (AF) in China and investigate the associations between prior anticoagulation therapy and initial stroke severity and in-hospital outcomes.
Source: International Journal of Cardiology - May 29, 2023 Category: Cardiology Authors: Lue Zhou, Yapeng Li, Xin Yang, Hongqiu Gu, Yanran Duan, Hang Fu, Anran Wang, Kai Liu, Yuan Gao, Bo Song, Yusheng Li, Yingyu Jiang, Jing Zhang, Chunjuan Wang, Meng Wang, Zixiao Li, Yuming Xu, Chengzeng Wang, Yongjun Wang Source Type: research

Stroke and urosepsis after discontinuation of rivaroxaban
We report a patient with stroke shortly after discontinuation of rivaroxaban with a complicated course.
Source: International Journal of Cardiology - November 4, 2013 Category: Cardiology Authors: Claudia Stöllberger, Josef Finsterer Tags: Online Letters to the Editor Source Type: research

Reasons for non-adherence to practice guidelines on stroke prevention in patients with atrial fibrillation: A cross-sectional study in primary care
Atrial fibrillation (AF) is associated with an increased risk of stroke and mortality if left untreated [1]. Anticoagulants – such as vitamin K antagonists (VKA) and non-VKA oral anticoagulants (NOACs) – are highly effective in preventing this [2], but inherently carry the risk of bleeding complications. To identify AF patients in whom stroke risk outweighs bleeding risk, practice guidelines recommend to use clinical decision rules. However, adherence to such guidelines is low [3]. Knowledge of the exact reasons for this non-adherence is scarce and mainly based on vignette studies or qualitative studies in which physic...
Source: International Journal of Cardiology - March 31, 2015 Category: Cardiology Authors: Sander van Doorn, Floor Hartman-Weide, Geert-Jan Geersing, Ruud Oudega, Arno W. Hoes, Frans H. Rutten Tags: Letter to the Editor Source Type: research

REal-LIfe Evidence of stroke prevention in patients with atrial Fibrillation – the RELIEF study
The objective of the ‘REal-LIfe Evidence on stroke prevention in patients with atrial Fibrillation’ (RELIEF) study was to compare the effectiveness of newly-initiated rivaroxaban or VKA therapy among NVAF patients in Germany.
Source: International Journal of Cardiology - September 21, 2015 Category: Cardiology Authors: Craig I. Coleman, Matthias Antz, Birgit Ehlken, Thomas Evers Source Type: research

REal-LIfe Evidence of stroke prevention in patients with atrial Fibrillation — The RELIEF study
The objective of the ‘REal-LIfe Evidence on stroke prevention in patients with atrial Fibrillation’ (RELIEF) study was to compare the effectiveness of newly-initiated rivaroxaban or VKA therapy among NVAF patients in Germany.
Source: International Journal of Cardiology - September 21, 2015 Category: Cardiology Authors: Craig I. Coleman, Matthias Antz, Birgit Ehlken, Thomas Evers Tags: Correspondence Source Type: research

Is left atrial appendage closure useful for stroke prevention in atrial fibrillation patients with renal failure?
With great interest we read the article by Kefer et al. about the impact of chronic kidney disease on left atrial appendage (LAA) occlusion with the ACP device for stroke prevention in patients with atrial fibrillation (AF) [1]. We agree with the authors that stroke prevention in AF patients with chronic kidney disease is a problem due to increased bleeding complications during oral anticoagulant therapy with vitamin K antagonists. Furthermore, the use of non-vitamin K-antagonist oral anticoagulants (NOACs) is dangerous or contraindicated in these patients.
Source: International Journal of Cardiology - April 14, 2016 Category: Cardiology Authors: Claudia Stöllberger, Josef Finsterer, Birke Schneider Source Type: research

Renal function, P-gp-affecting drugs and new anticoagulants for stroke prevention
New oral anticoagulants (NOAs), like the thrombin-inhibitor dabigatran etexilate or the factor Xa-inhibitor rivaroxaban showed similar efficacy as the vitamin-K-antagonist (VKA) warfarin for stroke prevention in patients with atrial fibrillation (AF) . One of the advantages of the NOAs, compared with VKAs, should be the lack of the necessity for laboratory monitoring and its lower rate of drug- and food interactions. The serum concentration of NOAs, however, is influenced by renal function. Furthermore, NOA-absorption is dependent on the intestinal P-glycoprotein (P-gp)-system, and P-gp activity is influenced by several dr...
Source: International Journal of Cardiology - February 11, 2013 Category: Cardiology Authors: Florian Höllerl, Claudia Stöllberger, Josef Finsterer Tags: Letters to the Editor Source Type: research

Recurrent stroke and myocardial infarction in a young woman with severe osteoporosis and hyperparathyroidism
We have taken great interest in the recently published article entitled “ Effect of calcium or vitamin D supplementation on vascular outcomes: A meta-analysis of randomized controlled trial” . Likewise, since parathormone (PTH) is a vasoactive peptide, we, herein, wish to draw attention to the fact that primary hyperparathyroidism (pHPT) can –as well– be in association with increased risk of cardiovascular diseases (i.e. myocardial infarction (MI), heart failure, thrombosis or cardioembolism, hypertension), stroke and osteoporosis . In this regard, we exemplify the clinical scenario of one of our pertinent patients.
Source: International Journal of Cardiology - January 21, 2014 Category: Cardiology Authors: Murat Kara, Levent Özçakar, Hatice Gözde Sümer, Timur Ekiz, Sibel Özbudak Demir, Ayşen Akıncı Tags: Online Letters to the Editor Source Type: research

Stroke risk reduction with oral anticoagulation using CHADS-VASc in a Japanese AF population: a modeling analysis
Current clinical guidelines recommend that risk stratification for ischaemic stroke in patients with nonvalvular AF (NVAF) should be performed using the CHA2DS2-VASc score (Congestive heart failure, Hypertension, Age≥75years [double], Diabetes mellitus, previous thromboembolism [double], Vascular disease, Age 65–74 years, and female gender) to aid decision making for antithrombotic treatment, with a preference for Non-Vitamin K Oral Anticoagulants (NOACs) in those with CHA2DS2-VASc score ≥1. However, CHA2DS2-VASc score is not recommended in the 2014 Japanese Circulation Society (JCS) guidelines for patients with NVAF.
Source: International Journal of Cardiology - December 5, 2014 Category: Cardiology Authors: Keitaro Senoo, Deirdre A. Lane, Gregory Y.H. Lip Source Type: research

Inadequate anticoagulation by Vitamin K antagonists and major adverse cardiovascular events other than stroke
I read the article by Pastori et al. [1] with great interest. In their artcile, the authors reported that inadequate anticoagulation by Vitamin K Antagonists was found to be associated with Major Adverse Cardiovascular Events (MACE) in patients with atrial fibrillation, and they concluded that time in therapeutic range (TTR) was an independent predictor of MACE in patients with atrial fibrillation. It is known that inadequate anticoagulation by Vitamin K Antagonists is a strong predictor of stroke.
Source: International Journal of Cardiology - October 30, 2015 Category: Cardiology Authors: Mehmet Eyuboglu Tags: Correspondence Source Type: research

Vitamin D and Cardiovascular Disease: From atherosclerosis to myocardial infarction and stroke
There continues to be interest in understanding the role of vitamin D in the pathogenesis, epidemiology and prevention of cardiovascular disease (CVD). In fact vitamin D deficiency has been associated to an increased risk of developing CVD given to the relationship between low vitamin D levels and obesity, diabetes mellitus, dyslipidaemia, endothelial dysfunction and hypertension. However, although vitamin D has been identified as a potentially important marker of CVD, the mechanisms through which vitamin D deficiency leads from endothelial dysfunction to myocardial infarction and stroke are not fully understood.
Source: International Journal of Cardiology - December 25, 2016 Category: Cardiology Authors: Giovanna Muscogiuri, Cedric Annweiler, Guillaume Duval, Spyridon Karras, Giacomo Tirabassi, Gianmaria Salvio, Giancarlo Balercia, Samantha Kimball, Kalliopi Kotsa, Luca Mascitelli, Harjit Pal Bhattoa, Annamaria Colao Tags: Review Source Type: research

Stroke risk assessment in atrial fibrillation: Beyond atrial rhythm
Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice, and is responsible for at least 20% of all strokes. Moreover, strokes associated to AF are largely avoidable, as the use of anti-vitamin K drugs can prevent>65% of all strokes, and direct oral anticoagulants con reduce the rate of stroke by a further 19% [1].
Source: International Journal of Cardiology - May 22, 2019 Category: Cardiology Authors: Giovanni Luca Botto, Francesco Maria Brasca Tags: Editorial Source Type: research

Pages: 1  2  3  4